Stage-Dependent Pathway Dominance in Alzheimer’s Disease: An Integrated Network of Amyloid-β, Tau, Synaptic Failure, and Neuroinflammation

Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder in which amyloid-β, tau pathology, synaptic dysfunction, and neuroinflammation interact across molecular, cellular, and network levels. Although these processes are well established individually, their reciprocal and stage-dependent relationships remain insufficiently integrated into a unified mechanistic framework. Age-related decline in proteostatic, metabolic, vascular, and immune resilience may further lower the threshold at which these interacting pathways become self-sustaining. This review therefore examines how protein aggregation, neuronal stress, and glial responses converge to shape disease progression. Summary: Amyloid-β oligomerization can disrupt synaptic signaling and calcium homeostasis, creating conditions that promote tau-directed kinase activation, tau hyperphosphorylation, mislocalization, and propagation. Pathological tau further compromises microtubule stability, axonal transport, synaptic function, and neuronal resilience. In parallel, microglial and astrocytic responses influence amyloid clearance, inflammatory signaling, blood-brain barrier integrity, and neuronal injury through pathways that include TREM2 and the NLRP3 inflammasome. These interactions generate feedback loops in which impaired clearance, proteinopathy, synaptic stress, and chronic inflammation can reinforce one another, while their relative contribution may vary across disease stages and individuals.Conclusion: Here we highlight AD as a dynamic mechanistic network rather than a fixed single-pathway cascade. The proposed framework distinguishes disease initiation from subsequent pathway dominance and amplification. Integrating amyloid, tau, synaptic, and neuroimmune processes may improve interpretation of disease heterogeneity, support multimodal biomarker strategies, and inform stage-matched therapeutic combinations. This framework also identifies causal direction, pathway dominance, and temporal transitions as priorities for future mechanistic and clinical research.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-16
DOI
https://doi.org/10.20944/preprints202611.1553.v1
Primary Topic
Alzheimer's disease research and treatments
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Stage-Dependent Pathway Dominance in Alzheimer’s Disease: An Integrated Network of Amyloid-β, Tau, Synaptic Failure, and Neuroinflammation

Rui Curi, Masaru Tanaka, Pedro Henrique Amorim Klauss, Raquel Batista Gritte et al.
Preprints.org
Alzheimer's disease research and treatments
preprint

Stage-Dependent Pathway Dominance in Alzheimer’s Disease: An Integrated Network of Amyloid-β, Tau, Synaptic Failure, and Neuroinflammation

Rui Curi, Masaru Tanaka, Pedro Henrique Amorim Klauss, Raquel Batista Gritte, Ashley Tang, Sophia Ferreira
preprint en

Abstract

Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder in which amyloid-β, tau pathology, synaptic dysfunction, and neuroinflammation interact across molecular, cellular, and network levels. Although these processes are well established individually, their reciprocal and stage-dependent relationships remain insufficiently integrated into a unified mechanistic framework. Age-related decline in proteostatic, metabolic, vascular, and immune resilience may further lower the threshold at which these interacting pathways become self-sustaining. This review therefore examines how protein aggregation, neuronal stress, and glial responses converge to shape disease progression. Summary: Amyloid-β oligomerization can disrupt synaptic signaling and calcium homeostasis, creating conditions that promote tau-directed kinase activation, tau hyperphosphorylation, mislocalization, and propagation. Pathological tau further compromises microtubule stability, axonal transport, synaptic function, and neuronal resilience. In parallel, microglial and astrocytic responses influence amyloid clearance, inflammatory signaling, blood-brain barrier integrity, and neuronal injury through pathways that include TREM2 and the NLRP3 inflammasome. These interactions generate feedback loops in which impaired clearance, proteinopathy, synaptic stress, and chronic inflammation can reinforce one another, while their relative contribution may vary across disease stages and individuals.Conclusion: Here we highlight AD as a dynamic mechanistic network rather than a fixed single-pathway cascade. The proposed framework distinguishes disease initiation from subsequent pathway dominance and amplification. Integrating amyloid, tau, synaptic, and neuroimmune processes may improve interpretation of disease heterogeneity, support multimodal biomarker strategies, and inform stage-matched therapeutic combinations. This framework also identifies causal direction, pathway dominance, and temporal transitions as priorities for future mechanistic and clinical research.

Preprints.org
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon